drugset

drugset / Trial / NCT00332293

AL-15469A for the Treatment of Bacterial Conjunctivitis

NCT00332293 ↗

Phase 3 Completed 695 enrolled Alcon Research

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Timeline

Start: 2006-05
Primary completion: 2006-12
Completion: 2006-12

Publications

Results Tauber S, Cupp G, Garber R, Bartell J, Vohra F, Stroman D. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. Adv Ther. 2011 Jul;28(7):566-74. doi: 10.1007/s12325-011-0037-x. Epub 2011 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Moxifloxacin	Small molecule	0.5 %	Other

Indications